CCCC
C4 Therapeutics Inc

2,327
Mkt Cap
$236.47M
Volume
894,951.00
52W High
$5.10
52W Low
$1.09
PE Ratio
-1.47
CCCC Fundamentals
Price
$2.46
Prev Close
$2.44
Open
$2.40
50D MA
$2.46
Beta
1.91
Avg. Volume
2.64M
EPS (Annual)
-$1.52
P/B
1.18
Rev/Employee
$323,490.91
Loading...
Loading...
News
all
press releases
FY2028 EPS Estimates for C4 Therapeutics Lowered by Analyst
C4 Therapeutics, Inc. (NASDAQ:CCCC - Free Report) - Investment analysts at Brookline Capital Management decreased their FY2028 EPS estimates for C4 Therapeutics in a report issued on Thursday...
MarketBeat·15d ago
News Placeholder
More News
News Placeholder
C4 Therapeutics (NASDAQ:CCCC) Issues Quarterly Earnings Results
C4 Therapeutics (NASDAQ:CCCC - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.47...
MarketBeat·17d ago
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +6.38% and +72.77%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·19d ago
News Placeholder
Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of +41.67% and +2.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
Precision Oncology Approaches Drive $312B Market Transformation
Precision Oncology Approaches Drive $312B Market Transformation Precision Oncology Approaches Drive $312B Market Transformation PR Newswire VANCOUVER, Oct. 17, 2025 USA News Group News Commentary...
PR Newswire·1mo ago
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) delivered earnings and revenue surprises of +16.67% and -1.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
chainwire·7mo ago
News Placeholder
PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (Seaport) a...
Business Wire·1y ago
News Placeholder
Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA), C4 Therapeutics (CCCC) and Lineage Therap (LCTX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Liquidia Technologies (LQDA Research Report), C4 Therapeutics...
TipRanks Financial Blog·1y ago

Latest CCCC News

View

Advertisement|Remove ads.

Advertisement|Remove ads.